{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:24:23Z","timestamp":1790605463784,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007867","name":"Universit\u00e9 Laval","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de recherche du Quebec Sante","doi-asserted-by":"publisher","award":["20067"],"award-info":[{"award-number":["20067"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004489","name":"Mitacs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.cellsig.2025.111588","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T21:05:19Z","timestamp":1736024719000},"page":"111588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Pharmacological characterization of cannabidiol as a negative allosteric modulator of the 5-HT2A receptor"],"prefix":"10.1016","volume":"127","author":[{"given":"Etienne","family":"Billard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Torbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Inserra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Bertazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"De Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Comai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chatenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence E.","family":"H\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.cellsig.2025.111588_bb0005","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cellsig.2025.111588_bb0010","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0269881120940937","article-title":"A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers","volume":"35","author":"Ramaekers","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.cellsig.2025.111588_bb0015","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/npp.2017.86","article-title":"Modern clinical research on LSD","volume":"42","author":"Liechti","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.cellsig.2025.111588_bb0020","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","volume":"46","author":"Holze","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111588_bb0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1124\/pharmrev.120.000056","article-title":"Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms","volume":"73","author":"Inserra","year":"2021","journal-title":"Pharmacol. Rev."},{"issue":"11","key":"10.1016\/j.cellsig.2025.111588_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17111953","article-title":"D-lysergic acid diethylamide (LSD) as a model of psychosis: mechanism of action and pharmacology","volume":"17","author":"De Gregorio","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cellsig.2025.111588_bb0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.cellsig.2025.111588_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112203","article-title":"A non-hallucinogenic LSD analog with therapeutic potential for mood disorders","volume":"42","author":"Lewis","year":"2023","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111588_bb0045","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1038\/s41467-023-44016-1","article-title":"Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential","volume":"14","author":"Wallach","year":"2023","journal-title":"Nat. Commun."},{"issue":"6579","key":"10.1016\/j.cellsig.2025.111588_bb0050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.abl8615","article-title":"Structure-based discovery of nonhallucinogenic psychedelic analogs","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111588_bb0055","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/j.pain.0000000000001386","article-title":"Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain","volume":"160","author":"De Gregorio","year":"2019","journal-title":"Pain"},{"issue":"10","key":"10.1016\/j.cellsig.2025.111588_bb0060","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","article-title":"Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb","volume":"30","author":"Izzo","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"issue":"10","key":"10.1016\/j.cellsig.2025.111588_bb0065","first-page":"485","article-title":"Antipsychotic effect of cannabidiol","volume":"56","author":"Zuardi","year":"1995","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.cellsig.2025.111588_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.cellsig.2025.111588_bb0075","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.cellsig.2025.111588_bb0080","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0269881108096519","article-title":"Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease","volume":"23","author":"Zuardi","year":"2009","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111588_bb0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0269881112460109","article-title":"Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment","volume":"27","author":"Englund","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.cellsig.2025.111588_bb0090","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41386-022-01478-z","article-title":"Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios","volume":"48","author":"Englund","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.cellsig.2025.111588_bb0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54752","article-title":"Assessment of orally administered \u03949-tetrahydrocannabinol when Coadministered with Cannabidiol on \u03949-tetrahydrocannabinol pharmacokinetics and pharmacodynamics in healthy adults: a randomized clinical trial","volume":"6","author":"Zamarripa","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"5","key":"10.1016\/j.cellsig.2025.111588_bb0100","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.cellsig.2025.111588_bb0105","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.cellsig.2025.111588_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl. Psychiatry"},{"issue":"5","key":"10.1016\/j.cellsig.2025.111588_bb0115","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00210-006-0033-x","article-title":"Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors","volume":"372","author":"Kathmann","year":"2006","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"8","key":"10.1016\/j.cellsig.2025.111588_bb0120","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"issue":"4","key":"10.1016\/j.cellsig.2025.111588_bb0125","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"43","key":"10.1016\/j.cellsig.2025.111588_bb0130","doi-asserted-by":"crossref","first-page":"16546","DOI":"10.1074\/jbc.RA118.004929","article-title":"Inhibitory effects of cannabidiol on voltage-dependent sodium currents","volume":"293","author":"Ghovanloo","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2025.111588_bb0135","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00213-021-05999-1","article-title":"Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey","volume":"239","author":"Kuc","year":"2021","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111588_bb0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s42238-024-00235-x","article-title":"Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado: characterizing enhancement and adverse reactions using mixed methods","volume":"6","author":"Piercey","year":"2024","journal-title":"J. Cannabis Res."},{"issue":"3","key":"10.1016\/j.cellsig.2025.111588_bb0145","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bph.15302","article-title":"Different responses of repetitive behaviours in juvenile and young adult mice to Delta(9) -tetrahydrocannabinol and cannabidiol may affect decision making for Tourette syndrome","volume":"178","author":"Gorberg","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.cellsig.2025.111588_bb0150","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020705118","article-title":"Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission","volume":"118","author":"De Gregorio","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"943","key":"10.1016\/j.cellsig.2025.111588_bb0155","article-title":"Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials","volume":"10","author":"Fuentes","year":"2020","journal-title":"Front. Psych."},{"issue":"559","key":"10.1016\/j.cellsig.2025.111588_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat1631","article-title":"Functional selectivity profiling of the angiotensin II type 1 receptor using pathway-wide BRET signaling sensors","volume":"11","author":"Namkung","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cellsig.2025.111588_bb0165","series-title":"Assay Guidance Manual","article-title":"Biosensor assays for measuring the kinetics of G-protein and arrestin-mediated signaling in live cells","author":"Hoare","year":"2004"},{"issue":"38","key":"10.1016\/j.cellsig.2025.111588_bb0170","first-page":"40154","article-title":"Exploring Druggable binding sites on the class A GPCRs using the residue interaction network and site identification by ligand competitive saturation","volume":"9","author":"Inan","year":"2024","journal-title":"ACS Omega"},{"issue":"4","key":"10.1016\/j.cellsig.2025.111588_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2020.129519","article-title":"Identification and characterization of fragment binding sites for allosteric ligand design using the site identification by ligand competitive saturation hotspots approach (SILCS-hotspots)","volume":"1864","author":"MacKerell","year":"2020","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"7183","key":"10.1016\/j.cellsig.2025.111588_bb0180","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Gonzalez-Maeso","year":"2008","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111588_bb0185","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71228-y","article-title":"The operational model of allosteric modulation of pharmacological agonism","volume":"10","author":"Jakubik","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111588_bb0190","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbr.2008.03.020","article-title":"Molecular biology of 5-HT receptors","volume":"195","author":"Hannon","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"1\u20132","key":"10.1016\/j.cellsig.2025.111588_bb0195","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0091-3057(01)00720-1","article-title":"5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens","volume":"72","author":"Rabin","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"3","key":"10.1016\/j.cellsig.2025.111588_bb0200","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0022-3565(25)22189-9","article-title":"Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis","volume":"246","author":"Sanders-Bush","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cellsig.2025.111588_bb0205","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2164-12-14","article-title":"Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis","volume":"12","author":"Atwood","year":"2011","journal-title":"BMC Genomics"},{"issue":"2","key":"10.1016\/j.cellsig.2025.111588_bb0210","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41594-018-0180-z","article-title":"Structures of the 5-HT(2A) receptor in complex with the antipsychotics risperidone and zotepine","volume":"26","author":"Kimura","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"12","key":"10.1016\/j.cellsig.2025.111588_bb0215","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.tips.2023.09.012","article-title":"Ligand selectivity hotspots in serotonin GPCRs","volume":"44","author":"Simon","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.cellsig.2025.111588_bb0220","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0028-3908(98)00208-1","article-title":"Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors","volume":"38","author":"Cheer","year":"1999","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111588_bb0225","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1527-3466.2007.00004.x","article-title":"Oleamide: a fatty acid amide signaling molecule in the cardiovascular system?","volume":"25","author":"Hiley","year":"2007","journal-title":"Cardiovasc. Drug. Rev."},{"issue":"25","key":"10.1016\/j.cellsig.2025.111588_bb0230","doi-asserted-by":"crossref","first-page":"14115","DOI":"10.1073\/pnas.94.25.14115","article-title":"Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide","volume":"94","author":"Thomas","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111588_bb0235","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0022-3565(24)29334-4","article-title":"Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems","volume":"299","author":"Fedorova","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.cellsig.2025.111588_bb0240","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nchembio.2527","article-title":"Structure-inspired design of \u03b2-arrestin-biased ligands for aminergic GPCRs","volume":"14","author":"McCorvy","year":"2018","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.cellsig.2025.111588_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.12.033","article-title":"Crystal structure of an LSD-bound human serotonin receptor","volume":"168","author":"Wacker","year":"2017","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.cellsig.2025.111588_bb0250","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of Cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.cellsig.2025.111588_bb0255","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/7854_2017_478","article-title":"Hallucinogens and serotonin 5-HT(2A) receptor-mediated signaling pathways","volume":"36","author":"L\u00f3pez-Gim\u00e9nez","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"20","key":"10.1016\/j.cellsig.2025.111588_bb0260","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.cellsig.2025.111588_bb0265","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.neuropharm.2011.05.023","article-title":"Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors","volume":"61","author":"Albizu","year":"2011","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.cellsig.2025.111588_bb0270","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1021\/acsomega.7b00629","article-title":"Existence of brain 5-HT1A-5-HT2A isoreceptor complexes with antagonistic allosteric receptor-receptor interactions regulating 5-HT1A receptor recognition","volume":"2","author":"Borroto-Escuela","year":"2017","journal-title":"ACS Omega"},{"issue":"19","key":"10.1016\/j.cellsig.2025.111588_bb0275","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1021\/acs.jmedchem.8b00789","article-title":"Discovery of new allosteric modulators of the Urotensinergic system through substitution of the urotensin II-related peptide (URP) phenylalanine residue","volume":"61","author":"Billard","year":"2018","journal-title":"J. Med. Chem."},{"issue":"43","key":"10.1016\/j.cellsig.2025.111588_bb0280","doi-asserted-by":"crossref","first-page":"16546","DOI":"10.1074\/jbc.RA118.004929","article-title":"Inhibitory effects of cannabidiol on voltage-dependent sodium currents","volume":"293","author":"Ghovanloo","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111588_bb0285","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/19336950.2019.1615824","article-title":"Cannabinoid interactions with ion channels and receptors","volume":"13","author":"Watkins","year":"2019","journal-title":"Channels"},{"key":"10.1016\/j.cellsig.2025.111588_bb0290","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.chemphyslip.2016.04.006","article-title":"Interaction of G protein coupled receptors and cholesterol","volume":"199","author":"Gimpl","year":"2016","journal-title":"Chem. Phys. Lipids"},{"issue":"6","key":"10.1016\/j.cellsig.2025.111588_bb0295","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1084\/jem.20120242","article-title":"Cannabinoids suppress inflammatory and neuropathic pain by targeting alpha3 glycine receptors","volume":"209","author":"Xiong","year":"2012","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.cellsig.2025.111588_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101301","article-title":"Cannabinoids and cannabinoid receptors: the story so far","volume":"23","author":"Shahbazi","year":"2020","journal-title":"iScience"},{"issue":"2","key":"10.1016\/j.cellsig.2025.111588_bb0305","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjp.0705607","article-title":"Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors","volume":"141","author":"Leggett","year":"2004","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.cellsig.2025.111588_bb0310","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/sj.bjp.0706643","article-title":"Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor","volume":"147","author":"Hoi","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111588_bb0315","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00000542-200101000-00022","article-title":"Anesthetic-like interaction of the sleep-inducing lipid oleamide with voltage-gated sodium channels in mammalian brain","volume":"94","author":"Nicholson","year":"2001","journal-title":"Anesthesiology"},{"key":"10.1016\/j.cellsig.2025.111588_bb0320","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/7854_2017_478","article-title":"Hallucinogens and serotonin 5-HT(2A) receptor-mediated signaling pathways","volume":"36","author":"Lopez-Gimenez","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"6","key":"10.1016\/j.cellsig.2025.111588_bb0325","article-title":"5-HT1A and 5-HT2A signaling, desensitization, and downregulation: serotonergic dysfunction and abnormal receptor density in schizophrenia and the prodrome","volume":"13","author":"Kim","year":"2021","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.cellsig.2025.111588_bb0330","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41380-024-02531-7","article-title":"Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT(2A) receptor","volume":"29","author":"Gaitonde","year":"2024","journal-title":"Mol. Psychiatry"},{"issue":"25","key":"10.1016\/j.cellsig.2025.111588_bb0335","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/0024-3205(95)00210-W","article-title":"The role of 5-HT2A receptors in antipsychotic activity","volume":"56","author":"Schmidt","year":"1995","journal-title":"Life Sci."},{"issue":"26","key":"10.1016\/j.cellsig.2025.111588_bb0340","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.2174\/1381612821666150605111236","article-title":"Atypical antipsychotics and inverse agonism at 5-HT2 receptors","volume":"21","author":"Sullivan","year":"2015","journal-title":"Curr. Pharm. Des."},{"issue":"8015","key":"10.1016\/j.cellsig.2025.111588_bb0345","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41586-024-07403-2","article-title":"Structural pharmacology and therapeutic potential of 5-methoxytryptamines","volume":"630","author":"Warren","year":"2024","journal-title":"Nature"}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656825000014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656825000014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:33:58Z","timestamp":1762317238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656825000014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":69,"alternative-id":["S0898656825000014"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2025.111588","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological characterization of cannabidiol as a negative allosteric modulator of the 5-HT2A receptor","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2025.111588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111588"}}